Patrick G. Enright, Director at Jazz Pharmaceuticals plc (JAZZ), sold 14,358 shares at $138.15 ($2.0M) on 2017-12-11, disclosed to the SEC on 2017-12-13.
Seasonal sale ($2.0M) by Director — this insider has traded JAZZ in December in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $138.15 | 800 | $111K | 5.5% |
| 2 | $139.56 | 5,358 | $748K | 37.3% |
| 3 | $139.56 | 5,358 | $748K | 37.3% |
| 4 | $140.50 | 2,842 | $399K | 19.9% |
| Total | $139.67 avg | 14,358 | $2.0M | 100% |
| Filing → |
| ZBIO | BUY | 2025-10-14 | $2.5M | — | Filing → |
| VERA | BUY | 2025-06-25 | $10.6M | — | Filing → |
| BIOA | BUY | 2024-09-27 | $7.2M | — | Filing → |